
Opinion|Videos|August 5, 2024
Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What is the potential role of value-based pricing models or alternative payment arrangements in improving access to CDK4/6 inhibitors for eligible patients?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Medicaid Work Requirements Mirror Programs in Georgia, Arkansas: Ciara Zachary, PhD, MPH
2
FDA Approves Sevabertinib for Nonsquamous NSCLC
3
How Effective and Safe Are GLP-1s for Weight Loss?
4
Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line
5













































